- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Multiple sclerosis
- Meeting Date: November 2021
- Public Summary Document (PSD) November 2021 PBAC Meeting - (PDF 1147KB)
- Public Summary Document (PSD) November 2021 PBAC Meeting - (Word 94KB)
Cladribine – November 2021
Cladribine: Tablet 10 mg; Mavenclad®
Last updated
18 March 2022